🔴 Optimi Health is trading 5.3% down today amid a 2.11% biotech-sector decline

Optimi Health is trading at $4.80 (-5.33%), with the move appearing more consistent with biotech-sector weakness.

• The biotech sector was down 2.11% during regular trading.
• On September 16, 2026, the company announced a Health Canada-authorized Phase 3 MDMA-assisted therapy trial for PTSD.
• The trial is expected to begin in 2027 and enroll up to 100 participants; no source directly attributes the decline to the announcement.